What is MOTS-c?
MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a small peptide encoded within mitochondrial DNA.
It’s part of an emerging class of “mitochondrial-derived peptides” that appear to act as metabolic regulators, drawing research interest for metabolism, aging, and exercise physiology.1
Benefits & what it’s studied for
Studied for effects on insulin sensitivity and glucose handling, mostly in animal models.
Research suggests roles in metabolic homeostasis and exercise capacity.
Investigated in the context of aging and mitochondrial function. Human clinical data is limited; we grade it Emerging.
How does MOTS-c work?
MOTS-c appears to influence metabolic pathways including AMPK signaling, which regulates cellular energy balance, and to translocate to the cell nucleus under metabolic stress to help regulate gene expression. This is the proposed basis for its metabolic effects.5
Dosing & administration
Research describes subcutaneous injection. Human dosing is not well-established.6
This is educational, not medical advice. We don’t publish dosing. Specific dosing should be determined by a licensed provider after evaluation.
Risks, side effects & safety
Human safety data is limited. Reported effects are mostly injection-site related; because it acts on metabolic and glucose pathways, anyone on diabetes medication or with metabolic conditions should only use it under medical supervision.7
Legality & status
MOTS-c was removed from Category 2 in April 2026 and is scheduled for PCAC review on July 23, 2026. Off Category 2 ≠ 503A-compoundable ≠ FDA-approved — three separate things, actively moving. Confirm with a licensed provider.3 See the full picture in our legality explainer.
Regulatory status as of June 2026 — reconfirm against the live FDA 503A list before go-live.
Thinking about MOTS-c?
Talk to a licensed provider who can tell you if it fits your goals — and build a safe protocol.
Research & references
- 1Lee C, et al. — MOTS-c & mitochondrial-derived peptides. Link to be finalized. link pending
- 2Preclinical insulin-sensitivity / exercise-capacity studies. Link to be finalized. link pending
- 3FDA — April 2026 Category 2 removal; PCAC July 23, 2026 docket; FDA-2025-N-6895. Confirm at publish. link pending
- 4MOTS-c in aging / mitochondrial-function research. Link to be finalized. link pending
- 5Mechanism literature (AMPK signaling, nuclear translocation). Link to be finalized. link pending
- 6Research dosing literature. Link to be finalized. link pending
- 7MOTS-c safety / tolerability literature. Link to be finalized. link pending
Reference links are illustrative placeholders — replace with verified PubMed/journal URLs before publishing.
Frequently asked questions
What is MOTS-c?+
A mitochondrial-derived peptide encoded in mitochondrial DNA, studied as a metabolic regulator.
What is MOTS-c used for?+
It’s studied for insulin sensitivity, metabolism, and exercise capacity — mostly in preclinical research.
Is MOTS-c legal?+
It came off Category 2 in April 2026 and is under PCAC review July 2026, but that’s not FDA approval. Confirm current status with a provider.
Does MOTS-c have human studies?+
Most evidence is preclinical; human data is limited, so we grade it Emerging.
Is MOTS-c safe?+
Human safety data is limited; because it affects metabolic pathways, medical supervision is important, especially for anyone on diabetes medication.